FDA Expects STD Claims Enforcement To Deter Future Violations
This article was originally published in The Tan Sheet
FDA will consider prosecuting executives of firms making unapproved sexually transmitted disease treatment claims for OTC drugs and nutritional products, the targets of its latest enforcement sweep.
You may also be interested in...
DoJ announces misdemeanor charges against firm warned about making unapproved claims of treating STDs and cancer for products marketed as dietary supplements, while FDA continues finding the banned weight loss drug sibutramine in products.
Diverting PSE for meth among four criminal charges against N.J. firms also marketing adulterated hoodia; and complaint on Florida firm's STD claims comes four years after warning about possible prosecutions.
““The Tan Sheet” provides links to previous articles on many of the enforcements DoJ announced from its year-long sweep.